Hypomorphic mutations in MRN complex genes are frequently found in cancer, supporting their role as oncosuppressors. However, unlike canonical oncosuppressors, MRN proteins are often overexpressed in tumor tissues, where they actively work to counteract DSBs induced by both oncogene-dependent RS and radio-chemotherapy. Moreover, at the same time, MRN genes are also essential genes, since the constitutive KO of each component leads to embryonic lethality. Therefore, even though it is paradoxical, MRN genes may work as oncosuppressive, oncopromoting, and essential genes. In this review, we discussed how alterations in the MRN complex impact the physiopathology of cancer, in light of our recent discoveries on the gene–dosage-dependent effect of NBS1 in Medulloblastoma. These updates aim to understand whether MRN complex can be realistically used as a prognostic/predictive marker and/or as a therapeutic target for the treatment of cancer patients in the future.

Autoimmune gastritis (AIG) in its advanced atrophic stage is characterized by reduced acid secretion, dysbiosis, and gastric cancer (GC) risk. Swallowed oral bacteria surviving in increased intragastric pH may play a carcinogenic role. Oral microbiota was linked to increased GC risk. In AIG, the concomitant assessment of oral and gastric microbiota has not yet been performed. This study aimed to investigate the oral and gastric microbiota in AIG patients to clarify the role of oral bacteria in gastric dysbiosis. A case–control study on n = 20 histologically diagnosed AIG patients and n = 20 controls without AIG is conducted. Saliva samples were obtained from subjects who were fasting and without toothbrushing. Within 1 h, gastroscopy with biopsies (for histopathology and DNA extraction) was performed. Saliva (n = 40) and biopsy (n = 40) samples were frozen at −20 °C. DNA was extracted and prepared; paired-end sequencing was performed (IlluminaMiSeq-sequencer, San Diego, CA, USA). Bacterial abundance in biopsies was higher in AIG than in controls (p = 0.06), but was not different in the saliva (p = 0.54) samples. In biopsies, AIG showed a lower Shannon-Index than controls (p = 0.001). In saliva studies, AIG showed a higher Shannon-Index than controls (p = 0.0). In biopsies, Streptococcus oralis, Fusobacterium pseudoperiodonticum, Veillonella rogosae, and Gemella sanguinis were more frequent in AIG (p < 0.03). The most abundantly shared taxa between saliva and biopsy were S. oralis and Prevotella histicola; Gemella sanguinis, Fusobacterium pseudoperidonticum, and Veillonella rogosae were shared in AIG patients only. This study confirmed gastric dysbiosis in AIG. Oral taxa were more commonly associated with AIG and shared between the mouth and the stomach. In AIG, the oral microbiota is associated with gastric dysbiosis, highlighting the importance of oral eubiosis in patients with impaired gastric acid secretion.

Background/Objectives: Metabolic alterations, including dyslipidemia, may influence tumor biology and treatment outcomes in neuroendocrine tumors. However, the clinical relevance of dyslipidemia and lipid-lowering therapy in bronchopulmonary neuroendocrine tumors (BP-NETs) treated with somatostatin analogues (SSAs) remains poorly defined. This translational proof-of-concept study evaluated progression-free survival (PFS) in patients with advanced BP-NETs receiving SSAs according to dyslipidemia and statin therapy and explored the effects of statin-SSA combination treatment in vitro. Methods: We retrospectively analyzed 24 patients with advanced well-differentiated BP-NETs treated with SSAs as first-line therapy. Fourteen patients (58.3%) had dyslipidemia, and 11 of them were receiving statins. In parallel, NCI-H727 cells were treated with atorvastatin (10 µM), lanreotide (5 or 10 µM), or their combination for 48–72 h. Cell viability, proliferation, cell death, apoptosis, DNA damage, and ATP production were assessed. Results: Median PFS was 22.5 months overall. A trend toward longer PFS was observed in non-dyslipidemic vs. dyslipidemic patients (70 vs. 36 months, p = 0.08). Among dyslipidemic patients, statin therapy was associated with a non-significant trend toward longer PFS compared with no statin therapy (36 vs. 18 months, p = 0.30). In vitro, combined atorvastatin–lanreotide treatment reduced cell viability and proliferation, increased cell death, enhanced cleaved caspase-3 and p-γH2AX expression, and reduced ATP production. Conclusions: These findings support the potential relevance of lipid metabolism modulation as an adjunct strategy in advanced BP-NETs while highlighting the need for larger prospective studies and dedicated biochemical investigation of the underlying lipid-related pathways.

Background/Objectives: Metabolic alterations, including dyslipidemia, are increasingly recognized in patients with neuroendocrine tumors and may influence tumor biology and treatment outcomes. However, the clinical relevance of dyslipidemia and the potential impact of lipid-lowering therapies in bronchopulmonary neuroendocrine tumors (BP-NETs) treated with somatostatin analogues (SSAs) remain poorly defined. This study aimed to evaluate the progression-free survival (PFS) in patients with advanced BP-NETs receiving SSAs according to dyslipidemia as well as statin therapy. In addition, an exploratory in vitro analysis was performed to assess the combined biological effect of statins and SSAs. Methods: This study investigated the combined effects of atorvastatin and lanreotide therapy both in vitro and in a clinical setting. In NCI-H727 cells, we assessed cell viability, proliferation, apoptosis, DNA damage, and metabolic activity following single and combined treatments. Concurrently, we retrospectively evaluated the impact of dyslipidemia and statin therapy on progression-free survival (PFS) in patients with advanced BP-NETs receiving SSAs. Results: Combined treatment resulted in reduced cell viability, proliferation, and ATP production, alongside increased apoptosis and DNA damage, and was associated with impaired cellular energy metabolism compared with lanreotide alone and control conditions. In the clinical analysis, dyslipidemia was associated with shorter progression-free survival (PFS), whereas atorvastatin therapy in dyslipidemic patients showed a positive trend toward improved PFS. Conclusions: These findings support the potential relevance of lipid metabolism modulation as an adjunct strategy in advanced BP-NETs, warranting further validation in larger prospective studies and encouraging additional biochemical investigation of the underlying pathways.